Condition: Histiocytosis · Sponsor: Anna Raciborska
Prospective, interventional, open, randomized, single-center, non-commercial clinical trial to optimize treatment and dosage of vemurafenib in juvenile patients with histiocytosis resistant to conventional therapy and in whom the BRAF gene mutation has been found.
This description comes directly from the study's public registry record.
Katarzyna Maleszewska · +48 22 32 77 205 · klinika.onkologii@imid.med.pl
Always discuss trial participation with your own doctor first.
| Mother and Child Institute | Warsaw, Mazovian, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04943198